Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study.


Journal

JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 30 10 2018
revised: 21 02 2019
accepted: 15 04 2019
entrez: 20 7 2019
pubmed: 20 7 2019
medline: 20 7 2019
Statut: ppublish

Résumé

After menopause, several androgens continue to be produced primarily by the adrenal glands; these can be converted into estrogens via aromatization or into androgen metabolites. It is unclear if androgens are associated with endometrial cancer risk independently of their being precursors to estrogens or if alternative metabolic pathways influence risk. We measured prediagnostic serum concentrations of 12 androgens and their metabolites using highly sensitive liquid chromatography-tandem mass spectrometry assays in a nested case-control study of postmenopausal women from the Women's Health Initiative Observational Study (313 endometrial cancer case subjects, 354 matched control subjects). Estrogens were previously assayed. We used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for endometrial cancer with adjustment for confounders. Compared to the lowest concentrations, the highest levels of adrenal androgens were associated with increased endometrial cancer risk: dehydroepiandrosterone (5th vs 1st quintile: OR = 1.85, 95% CI = 1.06 to 3.25), androstenedione (OR = 2.36, 95% CI = 1.34 to 4.16), and testosterone (OR = 1.91, 95% CI = 1.12 to 3.24). Downstream androgen metabolites were not associated with endometrial cancer. Although increased risks for the parent androgens were still suggested after adjustment for unconjugated estradiol, the associations attenuated, and with the exception of androstenedione, were no longer statistically significant. We also evaluated ratios of estrogens relative to their androgenic precursors; both higher unconjugated estrone:androstenedione and higher unconjugated estradiol:testosterone were associated with increased endometrial cancer risk. We identified increased risks for endometrial cancer with the highest levels of adrenal androgens and high levels of estrogens relative to these androgens. As adrenal androgens can be aromatized to estrogens, this suggests androgens likely influence endometrial carcinogenesis via estrogen metabolism.

Sections du résumé

BACKGROUND BACKGROUND
After menopause, several androgens continue to be produced primarily by the adrenal glands; these can be converted into estrogens via aromatization or into androgen metabolites. It is unclear if androgens are associated with endometrial cancer risk independently of their being precursors to estrogens or if alternative metabolic pathways influence risk.
METHODS METHODS
We measured prediagnostic serum concentrations of 12 androgens and their metabolites using highly sensitive liquid chromatography-tandem mass spectrometry assays in a nested case-control study of postmenopausal women from the Women's Health Initiative Observational Study (313 endometrial cancer case subjects, 354 matched control subjects). Estrogens were previously assayed. We used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for endometrial cancer with adjustment for confounders.
RESULTS RESULTS
Compared to the lowest concentrations, the highest levels of adrenal androgens were associated with increased endometrial cancer risk: dehydroepiandrosterone (5th vs 1st quintile: OR = 1.85, 95% CI = 1.06 to 3.25), androstenedione (OR = 2.36, 95% CI = 1.34 to 4.16), and testosterone (OR = 1.91, 95% CI = 1.12 to 3.24). Downstream androgen metabolites were not associated with endometrial cancer. Although increased risks for the parent androgens were still suggested after adjustment for unconjugated estradiol, the associations attenuated, and with the exception of androstenedione, were no longer statistically significant. We also evaluated ratios of estrogens relative to their androgenic precursors; both higher unconjugated estrone:androstenedione and higher unconjugated estradiol:testosterone were associated with increased endometrial cancer risk.
CONCLUSIONS CONCLUSIONS
We identified increased risks for endometrial cancer with the highest levels of adrenal androgens and high levels of estrogens relative to these androgens. As adrenal androgens can be aromatized to estrogens, this suggests androgens likely influence endometrial carcinogenesis via estrogen metabolism.

Identifiants

pubmed: 31321379
doi: 10.1093/jncics/pkz029
pii: pkz029
pmc: PMC6620792
doi:

Types de publication

Journal Article

Langues

eng

Pagination

pkz029

Subventions

Organisme : NIA NIH HHS
ID : HHSN271201100004C
Pays : United States

Références

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43
pubmed: 12496040
Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21
pubmed: 14575943
Ann Epidemiol. 2003 Oct;13(9 Suppl):S122-8
pubmed: 14575944
Int J Cancer. 2004 Jan 20;108(3):425-32
pubmed: 14648710
J Steroid Biochem Mol Biol. 2006 Jun;99(4-5):182-8
pubmed: 16621522
Anal Chem. 2007 Oct 15;79(20):7813-21
pubmed: 17848096
Endocr Relat Cancer. 2008 Jun;15(2):485-97
pubmed: 18509001
J Clin Endocrinol Metab. 2011 Feb;96(2):E330-9
pubmed: 21147881
Stat Methods Med Res. 2016 Oct;25(5):1925-1937
pubmed: 24108272
Lancet Oncol. 2014 Jun;15(7):e268-78
pubmed: 24872110
J Steroid Biochem. 1989 May;32(5):695-8
pubmed: 2525654
Compr Physiol. 2014 Oct;4(4):1369-81
pubmed: 25428847
Mol Cell Endocrinol. 2015 Feb 5;401:56-64
pubmed: 25475427
J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):56-62
pubmed: 26416142
Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):648-56
pubmed: 26908437
Br J Cancer. 2016 Mar 15;114(6):688-96
pubmed: 26930451
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1081-9
pubmed: 27197275
Endocr Relat Cancer. 2016 Jul;23(7):R323-35
pubmed: 27287451
Mol Cell Endocrinol. 2018 Apr 15;465:48-60
pubmed: 28919297
Int J Cancer. 2019 Jan 26;:null
pubmed: 30684389
Acta Obstet Gynecol Scand. 1985;64(3):209-12
pubmed: 3874514
J Clin Endocrinol Metab. 1997 Aug;82(8):2403-9
pubmed: 9253308
Control Clin Trials. 1998 Feb;19(1):61-109
pubmed: 9492970
Endocr Rev. 1998 Oct;19(5):593-607
pubmed: 9793759

Auteurs

Kara A Michels (KA)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Louise A Brinton (LA)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Nicolas Wentzensen (N)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Kathy Pan (K)

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.

Chu Chen (C)

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.

Garnet L Anderson (GL)

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.

Ruth M Pfeiffer (RM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Xia Xu (X)

Cancer Research Technology Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD.

Thomas E Rohan (TE)

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (TER).

Britton Trabert (B)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Classifications MeSH